⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

CLL is the most common adult leukemia — and it is often slow-growing. Many patients live for years or decades with CLL. Unlike acute leukemias, CLL does not always need immediate treatment. About one-third of CLL patients never need treatment at all.
Do not treat early-stage CLL without symptoms. Multiple trials have shown that treating asymptomatic early-stage CLL does not improve survival. “Watch and wait” with regular blood tests and check-ups is the correct approach until treatment criteria are met.
Two tests shape your entire treatment plan: IGHV mutation status and TP53/del(17p). IGHV-mutated CLL has a better prognosis and may be eligible for fixed-duration treatment. TP53 disruption (deletion 17p or TP53 mutation) means chemoimmunotherapy will not work — targeted therapy is mandatory.
BTK inhibitors have transformed CLL. Ibrutinib (2014), acalabrutinib (2019), and zanubrutinib (2023) are oral drugs that block a key survival signal in CLL cells. They are taken daily and produce high response rates across all risk groups including del(17p).
Venetoclax + obinutuzumab offers a fixed-duration alternative. The CLL14 trial showed that one year of venetoclax + obinutuzumab produces deep, durable remissions — especially in IGHV-mutated CLL. After 12 months, you stop treatment. Many patients remain in remission for 5+ years.
Pirtobrutinib is available for patients who fail other BTK inhibitors. Jaypirca (pirtobrutinib) is a next-generation, non-covalent BTK inhibitor approved for CLL patients who have tried and failed at least two prior therapies including a BTK inhibitor and a BCL-2 inhibitor.
Infections are the leading cause of illness and death in CLL. CLL itself suppresses the immune system. Many CLL treatments further weaken immunity. Infection prevention, vaccination, and monitoring immunoglobulin levels are essential parts of care.
Get to a CLL specialist. CLL treatment has changed dramatically since 2014. A hematologist with CLL expertise — or at least a second opinion from one — ensures you receive the best current treatment, not outdated regimens.

▼ Collapse

Understanding Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects a type of white blood cell called B lymphocytes. In CLL, the bone marrow produces too many abnormal B lymphocytes that do not function properly. These cells accumulate in the blood, bone marrow, lymph nodes, and spleen over time.

CLL is chronic — meaning it typically progresses slowly, over months to years, not days or weeks. Many patients are diagnosed incidentally when a routine blood test shows an elevated lymphocyte count. Some patients live with CLL for decades without ever needing treatment.

CLL and small lymphocytic lymphoma (SLL) are the same disease. When the abnormal cells are found mainly in the blood and bone marrow, it is called CLL. When they are found mainly in the lymph nodes, it is called SLL. Treatment is the same for both.

Approximately 20,000 new cases per year in the United States
The most common leukemia in adults in Western countries
Median age at diagnosis is about 70 years, but CLL can occur in younger adults
Slightly more common in men than women (approximately 1.5:1 ratio)
More common in people of European descent; rare in East Asian populations
Five-year relative survival rate is approximately 88%, though outcomes vary widely by risk group

The exact cause of CLL is unknown in most cases. Unlike some cancers, CLL is not caused by lifestyle factors, diet, or environmental exposures in most patients. Known risk factors include:

Family history: First-degree relatives of CLL patients have 6–9 times the risk of developing CLL. A small percentage of CLL cases are familial.
Agent Orange exposure: Veterans exposed to Agent Orange have an increased risk and may be eligible for VA benefits.
Age: Risk increases with age; CLL is uncommon under age 40.
Monoclonal B-cell lymphocytosis (MBL): A pre-CLL condition found in ~5% of adults over 60. Most people with MBL never develop CLL requiring treatment.

The most important concept in this guide: CLL treatment in 2026 is driven by two key molecular features: IGHV mutation status and TP53/del(17p) status. These determine whether you can use fixed-duration venetoclax-based therapy, whether chemoimmunotherapy is an option, and what your long-term outlook is likely to be. Insist on these tests before starting any treatment.

Key Breakthroughs in CLL

The CLL treatment landscape has been completely transformed since 2014, when the first BTK inhibitor was approved. Here are the most important advances:

FDA-APPROVED Bruton’s tyrosine kinase (BTK) inhibitors block a critical survival signal in CLL cells. Three covalent BTK inhibitors are FDA-approved for CLL:

Ibrutinib (Imbruvica, 2014): The first-in-class BTK inhibitor. Revolutionized CLL treatment. Taken continuously until progression or intolerance. Effective across all risk groups including del(17p). Cardiovascular side effects (atrial fibrillation, hypertension, bleeding) limit long-term use in some patients.
Acalabrutinib (Calquence, 2019): Second-generation BTK inhibitor with fewer off-target effects than ibrutinib. ELEVATE-TN trial showed superior PFS compared to obinutuzumab-chlorambucil. ELEVATE-RR trial showed non-inferior PFS to ibrutinib with fewer cardiovascular side effects.
Zanubrutinib (Brukinsa, 2023): Second-generation BTK inhibitor developed by BeiGene. ALPINE trial showed superior ORR and PFS compared to ibrutinib in relapsed/refractory CLL, with fewer cardiac side effects. Approved for CLL in the US in 2023.

FDA-APPROVED The CLL14 trial established venetoclax + obinutuzumab as a highly effective fixed-duration frontline regimen. Key features:

12 months of total treatment (obinutuzumab for first 6 cycles, venetoclax for 12 cycles), then stop
High rates of undetectable MRD (minimal residual disease) — approximately 76% in bone marrow
PFS benefit maintained at 6+ years of follow-up, especially in IGHV-mutated CLL
No continuous therapy needed — patients are treatment-free after 12 months
Preferred by NICE and many European guidelines over continuous BTKi for cost-effectiveness

FDA-APPROVED 2026 In February 2026 the FDA approved acalabrutinib (Calquence) in combination with venetoclax (Venclexta), with or without obinutuzumab, for adults with previously untreated CLL or small lymphocytic lymphoma (SLL). It is the first all-oral, fixed-duration frontline regimen — combining two targeted oral drugs instead of relying on an intravenous antibody backbone. Key features:

Based on the phase 3 AMPLIFY trial (NCT03836261), which compared acalabrutinib + venetoclax (± obinutuzumab) against standard chemoimmunotherapy (FCR or bendamustine-rituximab) in patients without del(17p) or TP53 mutation
Fixed-duration treatment, then stop — no indefinite daily BTK inhibitor required
All-oral option (the version without obinutuzumab avoids IV infusions entirely)
The approval applies to patients without del(17p) or TP53 mutation; for TP53-disrupted CLL, discuss other targeted options with your hematologist

Ask your hematologist: “Given my IGHV and TP53/del(17p) status, am I a candidate for a fixed-duration regimen like venetoclax + obinutuzumab or acalabrutinib + venetoclax, versus a continuous BTK inhibitor?”

FDA-APPROVED The MURANO trial showed that fixed-duration venetoclax + rituximab (2 years total) dramatically outperformed bendamustine-rituximab in relapsed CLL. Patients who achieved undetectable MRD had remarkably durable remissions — many still in remission at 5+ years of follow-up. This established venetoclax-based combinations as a key option in relapsed CLL.

FDA-APPROVED Pirtobrutinib is a first-in-class non-covalent (reversible) BTK inhibitor approved in 2023 for CLL/SLL patients who have received at least two prior lines of therapy including a BTK inhibitor and a BCL-2 inhibitor. Unlike ibrutinib, acalabrutinib, and zanubrutinib (which bind BTK permanently), pirtobrutinib binds reversibly and retains activity against the C481S BTK resistance mutation that causes failure of covalent BTK inhibitors. The BRUIN trial showed an ORR of approximately 73% in heavily pretreated patients.

EMERGING One of the most exciting developments in CLL is the concept of using MRD (measurable residual disease) testing to decide when to stop treatment. Trials are exploring whether patients who achieve undetectable MRD on venetoclax-based regimens can safely stop therapy earlier than planned, and whether patients on continuous BTK inhibitors who achieve deep responses might transition to a treatment-free period. This approach aims to minimize toxicity while maintaining disease control.

Diagnosis: The Tests You Need

CLL is often diagnosed from a routine blood test showing an elevated lymphocyte count. The workup confirms the diagnosis, identifies the specific biology of your CLL, and determines risk factors that guide treatment decisions.

CLL is suspected when a CBC shows a sustained absolute lymphocyte count of 5,000 or more per microliter. A peripheral blood smear typically shows small, mature-looking lymphocytes with “smudge cells” (fragile CLL cells that break apart during slide preparation). Many patients feel completely well at diagnosis.

Flow cytometry on peripheral blood is the key diagnostic test. CLL cells have a characteristic pattern of surface proteins: CD5+, CD19+, CD23+, weak CD20, weak surface immunoglobulin. This pattern distinguishes CLL from other B-cell lymphomas that can look similar. A bone marrow biopsy is usually not required for diagnosis — flow cytometry on blood is sufficient in most cases.

FISH testing looks for chromosomal abnormalities in CLL cells. The key findings are:

del(13q) (deletion of part of chromosome 13): The most common abnormality (~55%). When present alone, it is associated with favorable prognosis.
Trisomy 12 (extra copy of chromosome 12): Found in ~15%. Intermediate prognosis.
del(11q) (deletion of part of chromosome 11, including ATM gene): Found in ~15–20%. Associated with bulky lymphadenopathy and historically worse outcomes, though BTK inhibitors have improved this.
del(17p) (deletion of part of chromosome 17, including TP53 gene): Found in ~5–10% at diagnosis, more common at relapse. Associated with resistance to chemoimmunotherapy. Targeted therapy (BTK inhibitor or venetoclax-based) is required.

TP53 mutations can occur without del(17p) and have the same unfavorable implications. TP53 mutation testing by sequencing should be performed in addition to FISH for del(17p). Together, del(17p) and TP53 mutations are referred to as “TP53 disruption” and are found in approximately 10–15% of patients at first treatment. Chemoimmunotherapy does not work for TP53-disrupted CLL. These patients must receive targeted therapy.

IGHV (immunoglobulin heavy chain variable region) mutation status is one of the most important prognostic markers in CLL:

IGHV-mutated (~60% of CLL): Better prognosis. Responds well to fixed-duration venetoclax + obinutuzumab, with many patients achieving long-lasting remissions. Also responds well to chemoimmunotherapy (FCR) in younger patients.
IGHV-unmutated (~40% of CLL): More aggressive biology. Higher risk of progression and shorter remission duration with chemoimmunotherapy. BTK inhibitors and venetoclax combinations are preferred.

Important: IGHV mutation status does not change over time. It only needs to be tested once.

Key question for your hematologist: “Have you tested my CLL for IGHV mutation status, TP53 mutation, FISH panel (including del(17p), del(11q), del(13q), trisomy 12), and beta-2 microglobulin? I understand these results determine my treatment options.”

Prognostic Markers — What They Mean

Several tests help predict how your CLL will behave over time and which treatments are most appropriate.

Marker	Result	What It Means
IGHV-mutated	≥2% deviation from germline	Better prognosis. Excellent outcomes with fixed-duration venetoclax + obinutuzumab. FCR may produce very long remissions in fit younger patients.
IGHV-unmutated	<2% deviation from germline	More aggressive. Shorter remissions with chemoimmunotherapy. BTK inhibitors or venetoclax-based regimens preferred.
del(17p) / TP53 mutation	Present	Chemoimmunotherapy will not work. Targeted therapy (BTKi or venetoclax-based) is required. Higher risk of Richter transformation.
del(11q)	Present	Historically adverse, but responds well to BTK inhibitors. Often associated with bulky lymph nodes.
Beta-2 microglobulin	Elevated (>3.5 mg/L)	Higher tumor burden and/or more aggressive disease. Used in the CLL-IPI prognostic score.
Complex karyotype	≥3 abnormalities	Adverse prognosis. May reduce effectiveness of some targeted therapies. Being studied as an independent risk factor.

Important: Prognostic markers predict populations, not individuals. A patient with unfavorable markers can still achieve a long remission with modern targeted therapies. Conversely, favorable-risk patients can sometimes have unexpected disease progression.

Staging & When to Start Treatment

CLL staging uses two systems. Neither requires imaging scans — both rely on physical examination and blood counts.

Rai Stage (US)	Features	Risk
0	Lymphocytosis only (blood and marrow)	Low
I	Lymphocytosis + enlarged lymph nodes	Intermediate
II	Lymphocytosis + enlarged spleen and/or liver	Intermediate
III	Lymphocytosis + anemia (hemoglobin <11 g/dL)	High
IV	Lymphocytosis + thrombocytopenia (platelets <100,000)	High

Treatment is indicated when at least one of the following is present (iwCLL 2018 guidelines):

Progressive marrow failure: worsening anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelets <100,000)
Massive or progressive or symptomatic splenomegaly
Massive or progressive or symptomatic lymphadenopathy
Progressive lymphocytosis: >50% increase over 2 months, or lymphocyte doubling time <6 months
Autoimmune cytopenias (AIHA, ITP) that do not respond to steroids
Constitutional symptoms: unintentional weight loss ≥10% in 6 months, significant fatigue, fevers >100.5°F for ≥2 weeks without infection, drenching night sweats for ≥1 month

A rising lymphocyte count alone is NOT a reason to treat. Even lymphocyte counts over 100,000 do not require treatment if no other criteria are met.

What is my Rai stage?
What is my IGHV mutation status?
Do I have del(17p) or a TP53 mutation?
What are my FISH results?
Do I need treatment now, or can I safely watch and wait?
If I am watching and waiting, how often will I need blood tests and check-ups?
What symptoms should prompt me to contact you between appointments?
Should I see a CLL specialist for a second opinion?

BTK Inhibitors — Continuous Oral Therapy

BTK (Bruton’s tyrosine kinase) inhibitors block a critical enzyme that CLL cells need to survive and multiply. They are taken as oral pills, usually once or twice daily, and are continued until the disease progresses or side effects become unacceptable. BTK inhibitors work across all CLL risk groups, including del(17p)/TP53-mutated CLL.

FDA-APPROVED The first BTK inhibitor approved for CLL (2014). The RESONATE-2 trial (NCT01722487) showed dramatically superior PFS compared to chlorambucil in treatment-naive older patients. Ibrutinib is effective but has more off-target side effects than newer BTK inhibitors:

Atrial fibrillation: ~10–15% of patients; higher with longer use
Hypertension: ~20% of patients
Bleeding: Especially with anticoagulants; hold ibrutinib 3–7 days before surgery
Arthralgia: Joint pain, especially early in treatment
Dose: 420 mg once daily continuously

Ibrutinib is being largely replaced by acalabrutinib and zanubrutinib in many practice settings due to their improved cardiovascular safety profiles.

FDA-APPROVED Second-generation BTK inhibitor with greater selectivity for BTK, resulting in fewer off-target cardiovascular effects. Key trials:

ELEVATE-TN (NCT02475681): Acalabrutinib ± obinutuzumab vs. obinutuzumab-chlorambucil in treatment-naive CLL. Both acalabrutinib arms showed significantly superior PFS.
ELEVATE-RR (NCT02477696): Head-to-head vs. ibrutinib in relapsed CLL. Non-inferior PFS with significantly fewer cardiovascular events (atrial fibrillation, hypertension).
Dose: 100 mg twice daily continuously
Common side effects: Headache (often transient), diarrhea, bruising, cough
Note: Should not be taken with proton pump inhibitors (PPIs reduce absorption); use H2 blockers or antacids if needed, with 2-hour separation

FDA-APPROVED Second-generation BTK inhibitor developed by BeiGene (China). The ALPINE trial (NCT03734016) was the first randomized trial to show superior efficacy of one BTK inhibitor over another:

Superior overall response rate compared to ibrutinib (80.4% vs. 72.9%)
Superior PFS at 24 months compared to ibrutinib
Significantly lower rate of atrial fibrillation/flutter (2.5% vs. 10.1%)
Dose: 160 mg twice daily or 320 mg once daily continuously
Common side effects: Neutropenia (more common than with other BTKi), bruising, diarrhea, upper respiratory infections

Zanubrutinib is increasingly used as the preferred BTK inhibitor in many settings based on the ALPINE superiority data.

BTK inhibitor treatment is continuous. Unlike venetoclax-based regimens that have a fixed duration, BTK inhibitors are taken every day indefinitely until the disease progresses or side effects require stopping. This means years of daily medication and ongoing monitoring. Adherence is critical — missing doses can allow CLL cells to recover.

Venetoclax-Based Regimens — Fixed-Duration Treatment

Venetoclax (Venclexta) is a BCL-2 inhibitor that triggers programmed cell death (apoptosis) in CLL cells. Unlike BTK inhibitors, venetoclax-based regimens are given for a fixed duration (typically 12–24 months), after which treatment stops.

FDA-APPROVED The CLL14 trial (NCT02242942) compared venetoclax + obinutuzumab (12 cycles) vs. obinutuzumab + chlorambucil in treatment-naive CLL:

PFS dramatically superior: 6-year PFS 53.1% vs. 21.7% (Al-Sawaf et al., Blood 2024; median PFS 76.2 vs. 36.4 months, HR 0.40)
Undetectable MRD rates: ~76% in bone marrow at end of treatment
IGHV-mutated patients had remarkably long remissions — many still in remission at 6+ years
IGHV-unmutated and del(17p)/TP53-mutated patients also benefited, though duration of remission may be shorter

Treatment schedule:

Cycles 1–6: Obinutuzumab IV (cycle 1: 100 mg day 1, 900 mg day 2, 1000 mg days 8 and 15; cycles 2–6: 1000 mg day 1) + venetoclax oral daily (5-week ramp-up from 20 mg to 400 mg, then 400 mg daily)
Cycles 7–12: Venetoclax 400 mg daily (no obinutuzumab)
After cycle 12: Stop all treatment. Monitor regularly.

FDA-APPROVED For relapsed CLL, venetoclax + rituximab is given for a fixed 2-year duration. The MURANO trial (NCT02005471) showed vastly superior PFS compared to bendamustine-rituximab (median PFS not reached vs. 17 months at initial analysis). Patients achieving undetectable MRD had exceptionally durable remissions.

Venetoclax kills CLL cells very effectively. When large numbers of cells die quickly, their contents spill into the bloodstream, causing a potentially dangerous condition called tumor lysis syndrome (TLS). This is why venetoclax requires a mandatory 5-week dose ramp-up:

Week 1: 20 mg daily
Week 2: 50 mg daily
Week 3: 100 mg daily
Week 4: 200 mg daily
Week 5 onward: 400 mg daily

Before starting venetoclax, tumor burden is assessed (lymphocyte count, lymph node size) and patients are classified as low, medium, or high TLS risk. Higher-risk patients require hospitalization for the first dose(s), aggressive hydration, and frequent lab monitoring.

Fixed-duration vs. continuous: The choice between venetoclax-based fixed-duration therapy and continuous BTK inhibitor therapy is one of the most important decisions in CLL treatment. Both are excellent options. Key factors include: IGHV mutation status, patient preference for stopping treatment vs. continuous pill, cardiovascular risk factors, and drug interaction considerations.

Chemoimmunotherapy — A Declining Role

Before BTK inhibitors and venetoclax, chemoimmunotherapy (chemotherapy combined with anti-CD20 antibodies) was the standard treatment for CLL. It still has a limited role in specific situations.

FCR remains the only CLL regimen with proven potential for long-term, treatment-free remission approaching functional cure in a subset of patients. The MD Anderson long-term follow-up showed that approximately 50–60% of patients with IGHV-mutated CLL treated with FCR are still in remission at 12–15 years.

FCR is only appropriate for:

Young, fit patients (typically under age 65)
IGHV-mutated CLL without del(17p)/TP53 mutation
Good kidney function

FCR is NOT appropriate for: del(17p)/TP53-mutated CLL (will not work), IGHV-unmutated CLL (short remissions), older or less fit patients (too toxic). Even in its ideal population, FCR is increasingly being replaced by targeted therapy combinations.

BR is less intensive than FCR and was used for older patients before targeted therapies. It is now rarely recommended as frontline therapy because venetoclax + obinutuzumab and BTK inhibitors produce superior outcomes with acceptable toxicity. BR may still be used in resource-limited settings where targeted therapies are unavailable.

Based on my IGHV status and TP53/del(17p), what are my best treatment options?
Do you recommend a BTK inhibitor (continuous) or venetoclax-based (fixed-duration) approach?
What are the main side effects of each option?
If I choose venetoclax, what is my TLS risk and will I need hospitalization for the ramp-up?
If I choose a BTK inhibitor, how will you monitor for atrial fibrillation and hypertension?
Am I a candidate for FCR, and if so, what are the pros and cons vs. targeted therapy?
Will you test my MRD level during or after treatment?
Is there a clinical trial I should consider?
How will my immunoglobulin levels and infection risk be monitored during treatment?

MRD Monitoring — What It Means

Measurable residual disease (MRD) testing can detect CLL cells at extremely low levels — as few as 1 CLL cell among 10,000 normal cells. MRD testing is increasingly important in CLL, particularly with venetoclax-based regimens.

Undetectable MRD (uMRD): No CLL detected at the sensitivity of the test (usually 10^-4 or 10^-5). Associated with longer remission and better overall survival.
MRD-positive: CLL is still detectable. Does not necessarily mean treatment has failed, but is associated with earlier relapse.
Where to test: Both peripheral blood and bone marrow can be tested. Bone marrow is more sensitive. Many trials define uMRD in blood as the clinically relevant threshold.

MRD testing is most useful after venetoclax-based regimens, where achieving uMRD predicts long remission. For BTK inhibitors, most patients do not achieve uMRD (because BTK inhibitors control CLL rather than eliminating it), so MRD testing is less clinically useful during continuous BTKi therapy.

Ask your hematologist: “Will you test my MRD after treatment? What method will you use, and what will the results mean for my follow-up plan?”

Supportive Care & Infection Prevention

CLL causes immune deficiency even before treatment begins. The disease itself impairs normal antibody production, and CLL treatments further suppress immunity. Infections are the leading cause of morbidity and mortality in CLL patients.

CLL causes hypogammaglobulinemia (low antibody levels) in approximately 25–50% of patients, increasing infection risk
Immunoglobulin levels (IgG) should be monitored regularly
Patients with recurrent infections and IgG <500 mg/dL may benefit from IV or subcutaneous immunoglobulin replacement (IVIG/SCIG)
IVIG is expensive and requires infusions every 3–4 weeks; SCIG can be given at home weekly

Get vaccinated before starting treatment if possible — CLL and its treatments impair vaccine responses
Annual influenza vaccine recommended (inactivated, not live)
COVID-19 vaccines: Recommended, though response may be reduced. Boosters important
Pneumococcal vaccines (PCV20 or PCV15 + PPSV23): Recommended
Shingrix (recombinant zoster vaccine): Recommended; safe in immunocompromised patients
No live vaccines (MMR, live zoster, live yellow fever) during or after CLL treatment

CLL can trigger autoimmune cytopenias, where the immune system attacks the body’s own blood cells:

Autoimmune hemolytic anemia (AIHA): Antibodies destroy red blood cells, causing anemia, fatigue, jaundice. Occurs in ~5–10% of CLL patients. Treated with steroids; CLL-directed therapy may also be needed.
Immune thrombocytopenia (ITP): Antibodies destroy platelets, causing low platelet counts and bleeding risk. Less common than AIHA.
Pure red cell aplasia (PRCA): Rare. Bone marrow stops making red blood cells.

Important: Autoimmune cytopenias in CLL are treated differently from disease-related cytopenias. Steroids and immunosuppression are first-line; CLL treatment is added if the autoimmune process does not resolve.

CLL patients have an increased risk of developing other cancers, partly due to immune dysfunction and partly due to prior treatments. Skin cancers (both melanoma and non-melanoma) are particularly common. Maintain regular skin checks and age-appropriate cancer screening.

Relapsed and Refractory CLL

CLL commonly relapses after treatment, though this may take years. Treatment options at relapse depend on what you received previously, how long the remission lasted, and your current prognostic markers (which should be retested at relapse, as they can change).

Retest prognostic markers at relapse — TP53 mutations and del(17p) can be acquired at relapse even if absent at diagnosis
Switch drug class if possible: If relapse occurs on/after a BTK inhibitor, consider venetoclax-based therapy, and vice versa
Re-treatment with the same class: If remission lasted >2–3 years after a fixed-duration venetoclax regimen, re-treatment with venetoclax-based therapy may be effective
BTKi to BTKi switching: If ibrutinib intolerance (not resistance) led to stopping, switching to acalabrutinib or zanubrutinib may work. If resistance (disease progression on BTKi) is the issue, a different drug class is needed.

FDA-APPROVED Pirtobrutinib is a non-covalent BTK inhibitor that works differently from ibrutinib, acalabrutinib, and zanubrutinib. It retains activity against the C481S resistance mutation. The BRUIN trial (NCT03740529) showed an ORR of ~73% in CLL patients previously treated with covalent BTK inhibitors. Approved for patients who have received at least two prior therapies including a BTKi and a BCL-2 inhibitor.

Dose: 200 mg once daily continuously
Side effects: Generally well tolerated; lower rates of atrial fibrillation and bleeding than covalent BTKi

FDA-APPROVED Lisocabtagene maraleucel (Breyanzi, liso-cel) became the first CAR-T cell therapy approved for CLL/SLL in 2024, for patients who have received at least two prior therapies including a BTK inhibitor and a BCL-2 inhibitor. The TRANSCEND CLL 004 trial showed an ORR of ~45% and CR rate of ~18% in heavily pretreated patients. CAR-T is a complex, one-time treatment available only at specialized centers.

Allogeneic transplant is the only potentially curative treatment for CLL, but it is rarely performed because of its significant risks (treatment-related mortality ~15–25%) and because newer targeted therapies provide good disease control for most patients. Transplant may be considered for:

Young, fit patients with TP53-disrupted CLL who have exhausted targeted therapy options
Patients with Richter transformation who achieve remission
Patients who fail multiple lines of targeted therapy

Richter Transformation

Richter transformation occurs when CLL transforms into a more aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). This happens in approximately 2–10% of CLL patients over time and is a serious complication.

Warning signs include:

Rapidly growing lymph nodes
New B-symptoms (fever, drenching night sweats, weight loss) out of proportion to CLL disease status
Rapidly rising LDH level
Worsening performance status

A biopsy of a growing lymph node is required for diagnosis. PET-CT scanning can help identify the most suspicious nodes to biopsy.

Richter transformation is treated with aggressive lymphoma-directed therapy (R-CHOP or R-EPOCH), often followed by allogeneic stem cell transplant if remission is achieved. Prognosis is poor when the DLBCL is clonally related to the underlying CLL (which it is in ~80% of cases), with median survival of 6–12 months. Clinical trials should be strongly considered.

Should I have my TP53/del(17p) and IGHV status retested?
Based on my prior treatment, what is the best next option?
Am I eligible for pirtobrutinib or CAR-T cell therapy?
Should I be screened for Richter transformation?
Is allogeneic transplant a consideration for me?
What clinical trials are available for my situation?
Should I see a CLL specialist at this point if I have not already?

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

CLL research is very active, with multiple trials testing new combinations, MRD-guided strategies, and novel drug classes. Clinical trials offer access to treatments not yet commercially available.

Trial	Agent(s)	Population	NCT Number
CLL14	Venetoclax + obinutuzumab	Treatment-naive CLL (pivotal)	NCT02242942
MURANO	Venetoclax + rituximab	Relapsed/refractory CLL	NCT02005471
ALPINE	Zanubrutinib vs. ibrutinib	Relapsed/refractory CLL	NCT03734016
BRUIN	Pirtobrutinib (non-covalent BTKi)	R/R CLL after covalent BTKi	NCT03740529
TRANSCEND CLL 004	Liso-cel (CAR-T)	R/R CLL after BTKi + BCL-2i	NCT03331198
MAJIC	Acalabrutinib + venetoclax vs. venetoclax + obinutuzumab (MRD-guided)	Treatment-naive CLL	NCT05057494
Various BTKi + venetoclax	BTK inhibitor + venetoclax combos	Frontline and R/R CLL	Search ClinicalTrials.gov for “CLL venetoclax BTK”

ClinicalTrials.gov (clinicaltrials.gov): Search for “chronic lymphocytic leukemia” and filter by status (recruiting), location, and treatment type.
CLL Society (cllsociety.org): Patient advocacy organization with clinical trial matching and expert consultations.
Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center: 1-800-955-4572. Free nurse navigators.
Your academic hematology center: Many centers run CLL-specific trials not widely advertised.

International Access & Regulatory Landscape

CLL drug approvals and treatment preferences vary by country. Some important regional differences:

Drug	US FDA	EMA (Europe)	NICE (UK)	Notes
Ibrutinib	2014	2014	Recommended	First BTKi; being replaced by 2nd-gen agents globally
Acalabrutinib	2019	2020	Recommended	Preferred BTKi in many guidelines for better safety
Zanubrutinib	2023	2024	Under review	BeiGene (China-origin). Superior to ibrutinib in ALPINE. EMA CLL indication approved November 2024.
Venetoclax + obinutuzumab	2019	2020	Recommended (preferred)	NICE prefers over continuous BTKi for cost-effectiveness
Pirtobrutinib	2023	Pending	Not yet available	Non-covalent BTKi for post-BTKi failure
Liso-cel (CAR-T)	2024	Pending	Not yet available	First CAR-T for CLL; limited centers

Key regional difference: In the UK and much of Europe, NICE and national health systems prefer fixed-duration venetoclax + obinutuzumab over continuous BTK inhibitors for cost-effectiveness. In the US, both approaches are considered equally appropriate, with the choice driven more by patient factors and preference.

iwCLL (International Workshop on CLL): Publishes consensus criteria for diagnosis, response, and treatment indications
NCCN (US): Comprehensive CLL/SLL treatment algorithms updated multiple times yearly
ESMO (Europe): Clinical practice guidelines
BSH (British Society for Haematology): UK-specific guidelines
NICE (UK): Technology appraisals determining NHS access
GCLLSG (German CLL Study Group): Conducts many landmark CLL trials (CLL8, CLL10, CLL14)
Health Canada / CADTH: Canadian drug access pathway

Failed & De-Adopted Therapies

Understanding what has not worked or has been superseded is important for evaluating new options.

SUPERSEDED Chlorambucil (Leukeran) was the standard CLL treatment for decades. It produces low response rates, short remissions, and no survival benefit compared to modern therapies. It has been decisively replaced by targeted therapies in all guidelines. It should not be used as monotherapy in any setting where BTK inhibitors or venetoclax are available.

LIMITED USE Idelalisib, a PI3K delta inhibitor, was approved for relapsed CLL in 2014. However, significant toxicity issues have severely limited its use: autoimmune hepatitis (~15%), severe diarrhea/colitis (~15–20%), pneumonitis (~3%), and increased risk of opportunistic infections (CMV reactivation, Pneumocystis jirovecii). Multiple frontline trials using idelalisib were stopped early due to excess deaths. It is now rarely used because safer and more effective alternatives (BTK inhibitors, venetoclax) are available.

WITHDRAWN Duvelisib, a dual PI3K delta/gamma inhibitor, was approved for relapsed CLL in 2018 but voluntarily withdrawn from the US market in 2023 due to unfavorable benefit-risk profile in the era of BTK inhibitors and venetoclax. The DUO trial showed inferior OS compared to ofatumumab. Significant toxicity including infections, diarrhea, and hepatotoxicity.

DE-ADOPTED Alemtuzumab, an anti-CD52 antibody, was previously used for refractory CLL and del(17p) CLL before BTK inhibitors were available. It caused profound and prolonged immunosuppression with high rates of opportunistic infections. It has been completely replaced by BTK inhibitors and venetoclax for high-risk CLL and is no longer commercially available for hematologic indications.

FAILED Lenalidomide was studied extensively in CLL but never received FDA approval for this indication. The CONTINUUM trial (lenalidomide maintenance after first-line therapy) showed a PFS benefit but no OS benefit, with significant toxicity including tumor flare reactions, neutropenia, and second primary malignancies. It has been abandoned for CLL in favor of more effective targeted therapies.

Why this matters: If someone suggests one of these therapies, you now know its history. Always ask: “Is this the current standard treatment recommended by NCCN guidelines? Are there newer, better-tolerated options available?”

class="content-section" data-stage="resources">

Specialty Centers

CLL treatment has changed so rapidly that many community oncologists may not be fully up to date with the latest options. A consultation with a CLL specialist — even just for a second opinion — is strongly recommended, especially before starting first treatment, at relapse, or if you have high-risk features.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

Huntsman Cancer Institute (HCI) — University of Utah

NCI-designated Comprehensive Cancer Center with dedicated hematologic malignancies program

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: Hematologic Malignancies Program with CLL expertise, clinical trials portfolio including novel targeted therapy combinations, stem cell transplant program. ARUP Laboratories provides comprehensive CLL molecular diagnostics including IGHV sequencing, FISH panel, and TP53 mutation analysis.

Why it matters. HCI is the only NCI-designated Comprehensive Cancer Center in the Mountain West region. Its hematology program provides the full range of CLL treatments including BTK inhibitors, venetoclax-based regimens, and clinical trials with novel agents.

University of Utah Hematology — Outpatient Clinics

Location: Salt Lake City, UT
Phone: 801-585-2626
Services: CLL diagnosis, treatment, and monitoring. Referral to HCI for clinical trials and transplant evaluation.

Intermountain Health — Hematology/Oncology

Program: Hematology/Oncology services across Utah and the Intermountain West
Phone: 801-408-1100
Services: CLL management, community-based hematology-oncology, coordination with academic centers for complex cases.

Mayo Clinic Arizona

Location: 5777 E Mayo Blvd, Phoenix, AZ 85054
Phone: 480-301-8000
Programs: Hematologic malignancies program, CLL clinical trials.

University of Colorado Cancer Center

Location: Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO 80045
Phone: 720-848-0000
Programs: NCI-designated Comprehensive Cancer Center. CLL program with clinical trials.

MD Anderson Cancer Center

Location: Houston, TX · Phone: 877-632-6789
Pioneered many CLL treatment approaches including FCR. Large CLL clinical trial portfolio. Leading CLL research program globally.

Memorial Sloan Kettering Cancer Center

Location: New York, NY · Phone: 212-639-2000
Major lymphoma/CLL program. Active clinical trials including novel combinations and CAR-T.

Dana-Farber Cancer Institute

Location: Boston, MA · Phone: 617-632-3000
Harvard-affiliated. Leading CLL research including BTK inhibitor development. Large CLL-specific trials.

The Ohio State University Comprehensive Cancer Center

Location: Columbus, OH · Phone: 614-293-5066
Pioneered ibrutinib research. One of the largest CLL research programs in the US. Extensive clinical trials.

Mayo Clinic Rochester

Location: Rochester, MN · Phone: 507-538-3270
Comprehensive CLL program. Leading CLL prognostic research. Clinical trials.

Moffitt Cancer Center

Location: Tampa, FL · Phone: 888-663-3488
NCI-designated Comprehensive Cancer Center. Active CLL research and clinical trials.

City of Hope

Location: Duarte, CA · Phone: 626-256-4673
NCI-designated Comprehensive Cancer Center. CLL clinical trials and CAR-T program.

VA Hematologic Malignancies Care

The VA system provides CLL care through its network of medical centers. Veterans with CLL should be aware that Agent Orange exposure is a recognized risk factor, and affected veterans may be eligible for VA disability benefits. For complex CLL requiring specialist consultation, the VA coordinates with academic centers through community care arrangements.

Referral to an academic CLL center for second opinion
Community care authorization for specialist evaluation
Clinical trial access through VA-academic partnerships
Agent Orange-related benefits for eligible veterans

VA Cancer Care: cancer.va.gov
VA Community Care: 1-877-881-7618

Princess Margaret Cancer Centre (UHN), Toronto

Location: 610 University Avenue, Toronto, ON M5G 2M9
Phone: 416-946-4501
Programs: Comprehensive CLL program with clinical trials and molecular diagnostics.

BC Cancer — Vancouver Centre

Location: Vancouver, BC
Phone: 604-877-6000
Programs: Provincial CLL and lymphoma referral center. Clinical trials.

McGill University Health Centre, Montreal

Location: Montréal, QC
Phone: 514-934-1934
Programs: Hematology program with CLL expertise and clinical trials.

Leukemia & Lymphoma Society of Canada: llscanada.org
Canadian Cancer Society helpline: 1-888-939-3333

International Centers of Excellence for CLL

University of Cologne / GCLLSG, Germany: German CLL Study Group — conducted CLL8, CLL10, CLL14, and many other landmark trials
Royal Marsden Hospital, London, UK: Leading UK CLL research center
Karolinska Institute, Stockholm, Sweden: Major European CLL research and clinical program
Peter MacCallum Cancer Centre, Melbourne, Australia: Leading Australian CLL program with clinical trials
Peking University People’s Hospital, Beijing, China: Large CLL cohort; zanubrutinib development site

Caregiver Guidance

Caring for someone with CLL is different from caring for someone with an acute illness. CLL is typically a long-term condition that requires ongoing monitoring and, eventually, treatment that may continue for months to years.

This phase can be the hardest emotionally. Knowing your loved one has cancer but being told not to treat it feels counterintuitive. Trust the evidence — early treatment of asymptomatic CLL does not help.
Support regular monitoring. Help keep track of appointment schedules, blood test results, and any new symptoms to report.
Manage anxiety. Both patients and caregivers often experience significant anxiety during watch-and-wait. Professional psychological support may help.

Help with medication adherence. BTK inhibitors must be taken daily without interruption. Help establish a routine and monitor for missed doses.
Know the warning signs. Fever in a CLL patient on treatment is serious. Rapid lymph node growth, unexplained weight loss, or unusual bleeding should be reported promptly.
Infection prevention. CLL patients are immunocompromised. Hand hygiene, avoiding sick contacts, and food safety are important.
Manage side effects. Help track side effects and communicate them to the medical team. Some side effects (like atrial fibrillation on ibrutinib) require prompt medical attention.

CLL Society: cllsociety.org — CLL-specific patient support, Ask the Expert calls, clinical trial matching
Leukemia & Lymphoma Society (LLS): 1-800-955-4572 — peer-to-peer support, financial assistance, information
HealthTree for CLL: Online community connecting CLL patients
Caregiver support: CancerCare (1-800-813-4673) offers free counseling for caregivers

Fertility Preservation & Pregnancy with CLL

CLL is most common in older adults, but it does occur in people of reproductive age. If you are younger and newly diagnosed, discuss fertility preservation with your oncologist before starting any treatment.

Watch and wait (active surveillance)

If you are on active surveillance and not yet requiring treatment, pregnancy is often feasible with careful monitoring. Your hematologist will monitor your CLL closely throughout the pregnancy. CLL itself does not typically harm a developing baby. However, more frequent blood tests and surveillance are required.

Fertility preservation before CLL treatment

Women — standard chemotherapy regimens (FCR, bendamustine-based) damage eggs. Before starting treatment, ask about egg or embryo freezing (oocyte/embryo cryopreservation). A reproductive endocrinologist can usually arrange this within 2 weeks.
Men — sperm banking is simple and quick (1-3 days). Recommended before any cytotoxic chemotherapy.

Medications and pregnancy

BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) — animal studies show fetal harm. Both men and women taking these medications should use effective contraception. These drugs should not be used during pregnancy. If you become pregnant while taking a BTK inhibitor, contact your hematologist immediately.
Venetoclax (Venclexta) — limited data in humans; animal studies show harm. Avoid during pregnancy. Effective contraception required for women of childbearing potential and for male partners of women who may become pregnant.
Rituximab (Rituxan) and obinutuzumab (Gazyva) — these antibodies can cross the placenta after the first trimester and cause temporary B-cell depletion in the newborn. If a regimen including these drugs must be used during pregnancy, avoid use in the third trimester when possible; newborn immune function monitoring is required.
Chemotherapy (FCR, bendamustine) — generally contraindicated in the first trimester; limited use may be possible after the first trimester in life-threatening situations, with close fetal monitoring.

If you are of reproductive age with CLL: discuss contraception and fertility preservation at your first appointment. Most CLL patients in their 20s-40s have years on active surveillance before requiring treatment — this is often enough time to complete family planning.

Glossary

BCL-2: A protein that prevents cell death. Venetoclax blocks BCL-2, allowing CLL cells to die.
BTK (Bruton’s tyrosine kinase): An enzyme critical for CLL cell survival. Blocked by ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib.
CLL: Chronic lymphocytic leukemia. A slow-growing cancer of B lymphocytes. The most common adult leukemia.
Covalent BTK inhibitor: A BTK inhibitor that permanently binds to BTK (ibrutinib, acalabrutinib, zanubrutinib). Distinguished from non-covalent inhibitors (pirtobrutinib).
del(17p): Deletion of part of chromosome 17, including the TP53 gene. Confers resistance to chemoimmunotherapy.
del(11q): Deletion of part of chromosome 11. Associated with bulky lymph nodes and historically shorter remissions.
FISH: Fluorescence in situ hybridization. A test detecting specific chromosomal abnormalities in CLL cells.
Fixed-duration therapy: Treatment given for a set period (e.g., 12 months) and then stopped, as opposed to continuous therapy.
IGHV mutation status: Whether the immunoglobulin heavy chain variable region gene is mutated or unmutated. Major prognostic factor in CLL.
iwCLL: International Workshop on CLL. Publishes consensus criteria for CLL diagnosis, response, and treatment indications.
MBL: Monoclonal B-cell lymphocytosis. A pre-CLL condition. Most people with MBL never develop CLL requiring treatment.
MRD: Measurable (minimal) residual disease. Tiny amounts of CLL detectable by sensitive tests after treatment.
Obinutuzumab (Gazyva): A type II anti-CD20 antibody used with venetoclax in CLL. More effective than rituximab for CLL when combined with venetoclax or chlorambucil.
Pirtobrutinib (Jaypirca): A non-covalent (reversible) BTK inhibitor. Works against the C481S resistance mutation that causes failure of other BTK inhibitors.
Richter transformation: Transformation of CLL into a more aggressive lymphoma (usually DLBCL). A serious complication occurring in 2–10% of CLL patients.
Rituximab (Rituxan): A type I anti-CD20 antibody. Used in combination with venetoclax (MURANO) and with chemotherapy (FCR, BR).
SLL: Small lymphocytic lymphoma. The same disease as CLL but presenting mainly in lymph nodes rather than blood.
TLS: Tumor lysis syndrome. A dangerous condition caused by rapid cancer cell death, especially relevant with venetoclax.
TP53: Tumor protein p53. A tumor suppressor gene. When disrupted (by deletion or mutation), CLL is resistant to chemoimmunotherapy.
uMRD: Undetectable measurable residual disease. No CLL detected at the sensitivity of the test used. Associated with long remissions.
Venetoclax (Venclexta): A BCL-2 inhibitor. The key drug in fixed-duration CLL treatment regimens.
Watch and wait: Active surveillance without treatment for early-stage, asymptomatic CLL. Standard of care until treatment criteria are met.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians treating CLL across multiple countries. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
NCCN Guidelines for Clinicians — CLL/SLL (nccn.org) — Treatment algorithms followed by oncologists
CLL Society (cllsociety.org) — Patient education, clinical trial matching, expert consultations
Leukemia & Lymphoma Society (LLS) (lls.org) — Patient education, financial assistance, clinical trial support (1-800-955-4572)
National Cancer Institute (NCI) (cancer.gov) — Comprehensive CLL information

Key Guideline and Trial References

iwCLL 2018: Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
CLL14: Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. (NCT02242942)
MURANO: Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. (NCT02005471)
RESONATE-2: Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. (NCT01722487)
ELEVATE-TN: Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN). Lancet. 2020;395(10232):1278–1291. (NCT02475681)
ALPINE: Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319–332. (NCT03734016)
BRUIN: Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN). Lancet. 2021;397(10277):892–901. (NCT03740529)

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

Key Search Terms for ClinicalTrials.gov and PubMed

“chronic lymphocytic leukemia venetoclax obinutuzumab CLL14”
“ibrutinib CLL RESONATE-2”
“acalabrutinib CLL ELEVATE-TN”
“zanubrutinib ibrutinib CLL ALPINE”
“venetoclax rituximab relapsed CLL MURANO”
“pirtobrutinib non-covalent BTK CLL BRUIN”
“MRD guided CLL treatment discontinuation”

“lisocabtagene maraleucel CLL CAR-T TRANSCEND”
“BTK inhibitor venetoclax combination CLL”
“nemtabrutinib CLL”
“bispecific antibody CLL”
“Richter transformation CLL treatment”
“TP53 mutated CLL clinical trial”

A practical test for any online claim: If a website is making a claim about CLL treatment that does not appear anywhere in PubMed or NCCN guidelines, that should be a significant warning sign.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, stage, or treat anyone. It does not know your IGHV status, TP53 status, fitness level, comorbidities, or personal preferences. Only your medical team can build an actual plan.
CLL treatment is changing rapidly. New approvals, trial results, and guideline updates occur frequently. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual outcomes cannot be predicted. Prognostic markers describe populations, not individuals. Two patients with the same markers can have very different courses.
Treatment decisions are personal. The choice between continuous BTK inhibitor therapy and fixed-duration venetoclax-based therapy involves values and preferences that only you can weigh.

A final word. CLL is a serious diagnosis, but it is also one of the most treatable blood cancers. The treatment landscape has been completely transformed since 2014. Effective oral therapies, fixed-duration options, and emerging approaches like CAR-T mean that most CLL patients can expect years to decades of good quality of life. Get to a CLL specialist. Get your molecular testing. Ask about trials. Bring this guide to your appointments. You are not alone.